Loading…
A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection
Serological diagnostic tests are available that measure antibody levels against SARS-CoV-2 antigens. We utilized the Vaxarray Coronavirus (CoV) seroassay, which measures SARS-CoV-2 IgG antibodies against the full-length spike protein (FLS), receptor binding domain (RBD), and S2 extracellular domain...
Saved in:
Published in: | BMC infectious diseases 2024-11, Vol.24 (1), p.1308-11, Article 1308 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c457t-df80dc96955f09519b74beaf65021f66ab2ee90f7b1ed44f1b438ce8569e92713 |
container_end_page | 11 |
container_issue | 1 |
container_start_page | 1308 |
container_title | BMC infectious diseases |
container_volume | 24 |
creator | Porras, Francisco Mimica Pineda, Gabriel Mangilog, Abigail Hernandez, Keith Sikorski, Cynthia Lane, Michelle |
description | Serological diagnostic tests are available that measure antibody levels against SARS-CoV-2 antigens. We utilized the Vaxarray Coronavirus (CoV) seroassay, which measures SARS-CoV-2 IgG antibodies against the full-length spike protein (FLS), receptor binding domain (RBD), and S2 extracellular domain (ECD). Previous serological studies have used reference values that have not been validated and require many samples. Here, we show statistically established reference values determined using the upper tail of the Student t-distribution method. The target population was any personnel age 18 years and older working on a U.S. Navy ship, and vaccinated with Wuhan variant. The relative fluorescence mean (RFM) reference values for the full-length spike protein, RBD, and S2 ECD were 17,731, 13,990 and 9096, respectively. By using generalized non-parametric regression and reference values for the RBD spike protein and S2 ECD of SARS-CoV-2, this study was able to distinguish vaccine-mediated immune responses from natural infections. We provide the method and statistical code as a resource to determine future reference values for other serological assays. |
doi_str_mv | 10.1186/s12879-024-10117-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9586037f2a444564a69907ff97a492f8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A816301800</galeid><doaj_id>oai_doaj_org_article_9586037f2a444564a69907ff97a492f8</doaj_id><sourcerecordid>A816301800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-df80dc96955f09519b74beaf65021f66ab2ee90f7b1ed44f1b438ce8569e92713</originalsourceid><addsrcrecordid>eNqNks1u1DAUhSMEoqXwAiyQJTbtIsV2nNheVqMCI1WqxM9srRvnesajTFzspOrwHrwvnk6pOogFyiL29XeOlZNTFG8ZPWdMNR8S40rqknJRMsqYLOtnxTETkpW8qsTzJ-uj4lVKa0qZVFy_LI4qXQtVSXZc_LogaYTRp9Fb6Pstwbxte59W2JGIDiMOFskt9BOSDkeMGz_kIxciGVdIFnAHMcKWzEIMA9z6OCVyOguLM5IwBkgpn42B2BVEsFnuf-7crPVDvjUMBIaO5OUUoSd-cGh309fFCwd9wjcP75Pi-8fLb7PP5dX1p_ns4qq0opZj2TlFO6sbXdeO6prpVooWwTU15cw1DbQcUVMnW4adEI61olIWVd1o1Fyy6qSY7327AGtzE_0G4tYE8OZ-EOLSQMzJ9Gh0rRpaScdBCFE3AhqtqXROSxCaO5W9TvdeNzH8mHKMZuOTxb6HAcOUTJX_lpZaNjqj7_9C12GKQ_7STAnONRdPqSXk-3M2YcwR7kzNhWJNRZmiNFPn_6Dy0-HG2zCg83l-IDg7EGRmxLtxCVNKZv71y_-z14tDlu9ZG0NKuTqPeTJqdn01-76a3Fdz31dTZ9G7hySmdoPdo-RPQavfPWTjow</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3142292469</pqid></control><display><type>article</type><title>A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Porras, Francisco Mimica ; Pineda, Gabriel ; Mangilog, Abigail ; Hernandez, Keith ; Sikorski, Cynthia ; Lane, Michelle</creator><creatorcontrib>Porras, Francisco Mimica ; Pineda, Gabriel ; Mangilog, Abigail ; Hernandez, Keith ; Sikorski, Cynthia ; Lane, Michelle</creatorcontrib><description>Serological diagnostic tests are available that measure antibody levels against SARS-CoV-2 antigens. We utilized the Vaxarray Coronavirus (CoV) seroassay, which measures SARS-CoV-2 IgG antibodies against the full-length spike protein (FLS), receptor binding domain (RBD), and S2 extracellular domain (ECD). Previous serological studies have used reference values that have not been validated and require many samples. Here, we show statistically established reference values determined using the upper tail of the Student t-distribution method. The target population was any personnel age 18 years and older working on a U.S. Navy ship, and vaccinated with Wuhan variant. The relative fluorescence mean (RFM) reference values for the full-length spike protein, RBD, and S2 ECD were 17,731, 13,990 and 9096, respectively. By using generalized non-parametric regression and reference values for the RBD spike protein and S2 ECD of SARS-CoV-2, this study was able to distinguish vaccine-mediated immune responses from natural infections. We provide the method and statistical code as a resource to determine future reference values for other serological assays.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-024-10117-5</identifier><identifier>PMID: 39548371</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescent ; Adult ; Age composition ; Amino acids ; Analysis ; Antibodies ; Antibodies, Viral - blood ; Antigens ; Chronology ; Coronaviruses ; COVID-19 ; COVID-19 - blood ; COVID-19 - diagnosis ; COVID-19 - immunology ; COVID-19 Serological Testing - methods ; COVID-19 Serological Testing - standards ; COVID-19 Vaccines - immunology ; Cutoff ; Female ; Humans ; Humidity ; Immune response ; Immunoglobulin G ; Immunoglobulin G - blood ; Infections ; Male ; Manufacturers ; Medical care ; Middle Aged ; Military Personnel ; Naval vessels ; Nucleocapsid protein ; Pandemics ; Probability distribution ; Proteins ; Reagents ; Reference value ; Reference Values ; SARS-CoV-2 ; SARS-CoV-2 - immunology ; Serodiagnosis ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - immunology ; Spike protein ; Statistical analysis ; Student t- distribution ; Testing ; Utilization ; Vaccination ; Vaccines ; Vaxarray Coronavirus (CoV) seroassay ; Viral diseases ; Young Adult</subject><ispartof>BMC infectious diseases, 2024-11, Vol.24 (1), p.1308-11, Article 1308</ispartof><rights>2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c457t-df80dc96955f09519b74beaf65021f66ab2ee90f7b1ed44f1b438ce8569e92713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3142292469?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25733,27903,27904,36991,36992,38495,43874,44569</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39548371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Porras, Francisco Mimica</creatorcontrib><creatorcontrib>Pineda, Gabriel</creatorcontrib><creatorcontrib>Mangilog, Abigail</creatorcontrib><creatorcontrib>Hernandez, Keith</creatorcontrib><creatorcontrib>Sikorski, Cynthia</creatorcontrib><creatorcontrib>Lane, Michelle</creatorcontrib><title>A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Serological diagnostic tests are available that measure antibody levels against SARS-CoV-2 antigens. We utilized the Vaxarray Coronavirus (CoV) seroassay, which measures SARS-CoV-2 IgG antibodies against the full-length spike protein (FLS), receptor binding domain (RBD), and S2 extracellular domain (ECD). Previous serological studies have used reference values that have not been validated and require many samples. Here, we show statistically established reference values determined using the upper tail of the Student t-distribution method. The target population was any personnel age 18 years and older working on a U.S. Navy ship, and vaccinated with Wuhan variant. The relative fluorescence mean (RFM) reference values for the full-length spike protein, RBD, and S2 ECD were 17,731, 13,990 and 9096, respectively. By using generalized non-parametric regression and reference values for the RBD spike protein and S2 ECD of SARS-CoV-2, this study was able to distinguish vaccine-mediated immune responses from natural infections. We provide the method and statistical code as a resource to determine future reference values for other serological assays.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age composition</subject><subject>Amino acids</subject><subject>Analysis</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens</subject><subject>Chronology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 Serological Testing - methods</subject><subject>COVID-19 Serological Testing - standards</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Cutoff</subject><subject>Female</subject><subject>Humans</subject><subject>Humidity</subject><subject>Immune response</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Infections</subject><subject>Male</subject><subject>Manufacturers</subject><subject>Medical care</subject><subject>Middle Aged</subject><subject>Military Personnel</subject><subject>Naval vessels</subject><subject>Nucleocapsid protein</subject><subject>Pandemics</subject><subject>Probability distribution</subject><subject>Proteins</subject><subject>Reagents</subject><subject>Reference value</subject><subject>Reference Values</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - immunology</subject><subject>Serodiagnosis</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>Spike protein</subject><subject>Statistical analysis</subject><subject>Student t- distribution</subject><subject>Testing</subject><subject>Utilization</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaxarray Coronavirus (CoV) seroassay</subject><subject>Viral diseases</subject><subject>Young Adult</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1u1DAUhSMEoqXwAiyQJTbtIsV2nNheVqMCI1WqxM9srRvnesajTFzspOrwHrwvnk6pOogFyiL29XeOlZNTFG8ZPWdMNR8S40rqknJRMsqYLOtnxTETkpW8qsTzJ-uj4lVKa0qZVFy_LI4qXQtVSXZc_LogaYTRp9Fb6Pstwbxte59W2JGIDiMOFskt9BOSDkeMGz_kIxciGVdIFnAHMcKWzEIMA9z6OCVyOguLM5IwBkgpn42B2BVEsFnuf-7crPVDvjUMBIaO5OUUoSd-cGh309fFCwd9wjcP75Pi-8fLb7PP5dX1p_ns4qq0opZj2TlFO6sbXdeO6prpVooWwTU15cw1DbQcUVMnW4adEI61olIWVd1o1Fyy6qSY7327AGtzE_0G4tYE8OZ-EOLSQMzJ9Gh0rRpaScdBCFE3AhqtqXROSxCaO5W9TvdeNzH8mHKMZuOTxb6HAcOUTJX_lpZaNjqj7_9C12GKQ_7STAnONRdPqSXk-3M2YcwR7kzNhWJNRZmiNFPn_6Dy0-HG2zCg83l-IDg7EGRmxLtxCVNKZv71y_-z14tDlu9ZG0NKuTqPeTJqdn01-76a3Fdz31dTZ9G7hySmdoPdo-RPQavfPWTjow</recordid><startdate>20241115</startdate><enddate>20241115</enddate><creator>Porras, Francisco Mimica</creator><creator>Pineda, Gabriel</creator><creator>Mangilog, Abigail</creator><creator>Hernandez, Keith</creator><creator>Sikorski, Cynthia</creator><creator>Lane, Michelle</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20241115</creationdate><title>A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection</title><author>Porras, Francisco Mimica ; Pineda, Gabriel ; Mangilog, Abigail ; Hernandez, Keith ; Sikorski, Cynthia ; Lane, Michelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-df80dc96955f09519b74beaf65021f66ab2ee90f7b1ed44f1b438ce8569e92713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age composition</topic><topic>Amino acids</topic><topic>Analysis</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens</topic><topic>Chronology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 Serological Testing - methods</topic><topic>COVID-19 Serological Testing - standards</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Cutoff</topic><topic>Female</topic><topic>Humans</topic><topic>Humidity</topic><topic>Immune response</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Infections</topic><topic>Male</topic><topic>Manufacturers</topic><topic>Medical care</topic><topic>Middle Aged</topic><topic>Military Personnel</topic><topic>Naval vessels</topic><topic>Nucleocapsid protein</topic><topic>Pandemics</topic><topic>Probability distribution</topic><topic>Proteins</topic><topic>Reagents</topic><topic>Reference value</topic><topic>Reference Values</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - immunology</topic><topic>Serodiagnosis</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>Spike protein</topic><topic>Statistical analysis</topic><topic>Student t- distribution</topic><topic>Testing</topic><topic>Utilization</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaxarray Coronavirus (CoV) seroassay</topic><topic>Viral diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Porras, Francisco Mimica</creatorcontrib><creatorcontrib>Pineda, Gabriel</creatorcontrib><creatorcontrib>Mangilog, Abigail</creatorcontrib><creatorcontrib>Hernandez, Keith</creatorcontrib><creatorcontrib>Sikorski, Cynthia</creatorcontrib><creatorcontrib>Lane, Michelle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Porras, Francisco Mimica</au><au>Pineda, Gabriel</au><au>Mangilog, Abigail</au><au>Hernandez, Keith</au><au>Sikorski, Cynthia</au><au>Lane, Michelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2024-11-15</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>1308</spage><epage>11</epage><pages>1308-11</pages><artnum>1308</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Serological diagnostic tests are available that measure antibody levels against SARS-CoV-2 antigens. We utilized the Vaxarray Coronavirus (CoV) seroassay, which measures SARS-CoV-2 IgG antibodies against the full-length spike protein (FLS), receptor binding domain (RBD), and S2 extracellular domain (ECD). Previous serological studies have used reference values that have not been validated and require many samples. Here, we show statistically established reference values determined using the upper tail of the Student t-distribution method. The target population was any personnel age 18 years and older working on a U.S. Navy ship, and vaccinated with Wuhan variant. The relative fluorescence mean (RFM) reference values for the full-length spike protein, RBD, and S2 ECD were 17,731, 13,990 and 9096, respectively. By using generalized non-parametric regression and reference values for the RBD spike protein and S2 ECD of SARS-CoV-2, this study was able to distinguish vaccine-mediated immune responses from natural infections. We provide the method and statistical code as a resource to determine future reference values for other serological assays.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>39548371</pmid><doi>10.1186/s12879-024-10117-5</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2334 |
ispartof | BMC infectious diseases, 2024-11, Vol.24 (1), p.1308-11, Article 1308 |
issn | 1471-2334 1471-2334 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_9586037f2a444564a69907ff97a492f8 |
source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | Adolescent Adult Age composition Amino acids Analysis Antibodies Antibodies, Viral - blood Antigens Chronology Coronaviruses COVID-19 COVID-19 - blood COVID-19 - diagnosis COVID-19 - immunology COVID-19 Serological Testing - methods COVID-19 Serological Testing - standards COVID-19 Vaccines - immunology Cutoff Female Humans Humidity Immune response Immunoglobulin G Immunoglobulin G - blood Infections Male Manufacturers Medical care Middle Aged Military Personnel Naval vessels Nucleocapsid protein Pandemics Probability distribution Proteins Reagents Reference value Reference Values SARS-CoV-2 SARS-CoV-2 - immunology Serodiagnosis Serology Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - immunology Spike protein Statistical analysis Student t- distribution Testing Utilization Vaccination Vaccines Vaxarray Coronavirus (CoV) seroassay Viral diseases Young Adult |
title | A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A25%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20statistically%20established%20reference%20value%20determined%20for%20the%20Vaxarray%20Coronavirus%20(CoV)%20seroassay%20to%20characterize%20vaccination%20and%20natural%20infection&rft.jtitle=BMC%20infectious%20diseases&rft.au=Porras,%20Francisco%20Mimica&rft.date=2024-11-15&rft.volume=24&rft.issue=1&rft.spage=1308&rft.epage=11&rft.pages=1308-11&rft.artnum=1308&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-024-10117-5&rft_dat=%3Cgale_doaj_%3EA816301800%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c457t-df80dc96955f09519b74beaf65021f66ab2ee90f7b1ed44f1b438ce8569e92713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3142292469&rft_id=info:pmid/39548371&rft_galeid=A816301800&rfr_iscdi=true |